InstalabLoading...
InstalabLoading...
If you have high blood pressure, one of the most important questions you can ask is: why? PRA (plasma renin activity) helps answer that question by revealing whether your body's primary blood pressure control system is behaving normally or has gone off track.
Renin is an enzyme your kidneys release into the bloodstream. It kicks off a hormonal chain reaction called the renin-angiotensin-aldosterone system, or RAAS, which controls how much salt and water your body retains and how tightly your blood vessels constrict. When renin is high, your body is actively trying to raise blood pressure. When renin is suppressed, something else may be driving your pressure up, and that distinction matters enormously for treatment.
The single most important use of this test is screening for a condition called primary aldosteronism, or PA. In PA, the adrenal glands (small hormone-producing organs that sit on top of your kidneys) pump out too much aldosterone, a hormone that tells your kidneys to retain salt and shed potassium. The excess aldosterone drives up blood pressure on its own, so renin drops to very low levels because the body no longer needs it. Catching this pattern is the key reason to check your PRA.
Primary aldosteronism is far more common than most people realize. Among those with resistant hypertension (blood pressure that stays elevated despite three or more medications), roughly 20 to 35% have PA as the underlying cause. Even among people with milder, stage 1 hypertension, the prevalence is approximately 5 to 10%, rising to 11 to 22% in stage 2 hypertension.
Despite these numbers, screening rates remain exceptionally low. That means a large number of people are being treated with generic blood pressure medications when they actually have a specific, often curable hormonal condition. If you have high blood pressure and no one has ever checked your renin and aldosterone levels, this test is worth pursuing.
PRA is not a simple snapshot of how much renin protein is in your blood. Instead, the lab takes your plasma, incubates it under controlled conditions, and measures how much angiotensin I (the first product renin creates) is generated over a set period. The result is expressed as ng/mL/h, essentially a speed measurement of renin's enzymatic activity. An alternative test called direct renin concentration, or DRC, measures the renin protein itself rather than its activity. Both can be used for screening.
Blood should be drawn in the morning after you have been seated for at least 30 minutes. Potassium should be measured at the same time, because low potassium can artificially suppress aldosterone and distort the results. One practical note: if your sample needs to be stored before processing, it should stay at room temperature. Refrigerating the sample can activate an inactive form of renin (called prorenin) and throw off the measurement.
PRA is almost always interpreted alongside aldosterone, not in isolation. The combination of the two values, expressed as the aldosterone-to-renin ratio (ARR), is what makes the screening powerful. Many common blood pressure medications can shift your renin and aldosterone levels, so it is essential to know which drugs you are taking before interpreting results.
A positive screen for primary aldosteronism requires all three of the following:
If your renin is very low but your aldosterone is only marginally elevated, the ratio can appear high even without true aldosteronism. That is why guidelines emphasize that the ratio should not be interpreted in isolation. A genuinely positive screen shows suppressed renin and meaningfully elevated aldosterone together.
Beyond primary aldosteronism, the pattern of renin and aldosterone together can point toward other conditions. High renin with high aldosterone may reflect kidney artery narrowing or volume depletion. Low renin with low aldosterone can suggest other rare genetic conditions affecting how your body handles salt.
The 2025 ACC/AHA hypertension guidelines specifically recommend screening in these groups:
| Who Should Be Screened | Why |
|---|---|
| People with resistant hypertension (uncontrolled on 3+ medications) | About 20 to 35% have primary aldosteronism as the underlying cause |
| People with hypertension plus low potassium | Classic pattern of aldosterone excess, though only about 30% of PA cases show low potassium |
| People with hypertension and an adrenal mass found incidentally on imaging | The mass may be an aldosterone-producing tumor |
| People with hypertension and obstructive sleep apnea | High prevalence of PA in this population |
| People with early-onset hypertension or stroke at a young age | May indicate a hereditary form of aldosteronism |
Sources: 2025 ACC/AHA Hypertension Guideline; 2025 Endocrine Society Clinical Practice Guideline; Quencer et al.
What this means for you: if you fall into any of these groups and have never had your renin and aldosterone measured, you may be managing a treatable hormonal condition with medications that only address the symptom. Getting screened can fundamentally change your treatment plan.
Because PRA reflects a dynamic hormonal system, many common medications shift it substantially. Understanding these effects matters both for accurate testing and for using renin levels to guide therapy.
Medications that suppress renin (and can cause a falsely positive aldosterone-to-renin ratio): beta-blockers, central alpha-2 agonists (like clonidine), and direct renin inhibitors (like aliskiren). If you are taking any of these and your screening comes back positive, the result may need to be repeated after switching to a medication that does not interfere.
Medications that raise renin (and can cause a falsely negative ratio): ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, and certain calcium channel blockers (the dihydropyridine type, such as amlodipine). These drugs stimulate the RAAS system, which pushes renin up and can mask aldosterone excess.
Medications that must be stopped at least four weeks before testing: mineralocorticoid receptor antagonists, including spironolactone, eplerenone, and amiloride. These directly block aldosterone's effects and take weeks to fully wash out of your system.
If you cannot safely stop interfering medications, your results can sometimes still be interpreted in clinical context. Alternatively, your clinician may temporarily switch you to non-interfering agents such as verapamil, hydralazine, or alpha-1 blockers for two to four weeks before retesting.
Renin profiling can also guide the choice of blood pressure medication, especially in resistant hypertension. Research on physiologically individualized therapy suggests three patterns:
This approach treats the hormonal profile rather than the blood pressure reading alone, and it may help you and your clinician find the right medication faster if standard approaches have not worked.